Deals

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally
CancerGlaxoSmithKline

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced the completion of the transaction under its exclusive development and license agreement with GlaxoSmithKline ("GSK"), granting a subsidiary of GSK the exclusive…

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BCHT BiotechnologymRNA

Changchun BCHT Biotechnology to Acquire Full Stake in mRNA R&D Firm Transcend Biomedical

FinanceWorg Pharmaceuticals

Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion

ADC / XDCBiotech

Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share

ADC / XDCCRO / CMO / CDMO

Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics

Show More